MOONLAKE IMMUNOTHERAPEUTICS: 10-K filed 2022-02-17
What MOONLAKE IMMUNOTHERAPEUTICS reported in its annual report filed 2022-02-17 (fiscal FY 2021): 17 published measures, 32 facts as tagged in accession 0001213900-22-008253.
This filing
- Form
- 10-K (annual report)
- Filed
- 2022-02-17
- Fiscal period
- fiscal FY 2021
- Accession
- 0001213900-22-008253 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MOONLAKE IMMUNOTHERAPEUTICS filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 115,836,314 | USD | |
| At 2020-12-31 | 116,633,898 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 7,895,251 | USD | |
| At 2020-12-31 | 4,150,183 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | -7,058,937 | USD | |
| At 2020-12-31 | -2,516,285 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 666,790 | USD | |
| At 2020-12-31 | 1,335,924 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-12-31 | -4,542,654 | USD | 365 |
| 2020-08-13 to 2020-12-31 | -90,838 | USD | 141 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-12-31 | -611,071 | USD | 365 |
| 2020-08-13 to 2020-12-31 | -316,692 | USD | 141 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-12-31 | -58,063 | USD | 365 |
| 2020-08-13 to 2020-12-31 | 116,652,616 | USD | 141 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-08-13 to 2020-12-31 | -115,000,000 | USD | 141 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | -7,059,268 | USD | |
| At 2020-12-31 | -2,516,616 | USD |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-12-31 | 360,000,000 | shares | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-12-31 | -4,570,345 | USD | 365 |
| 2020-08-13 to 2020-12-31 | -105,755 | USD | 141 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 793,706 | USD | |
| At 2020-12-31 | 1,618,981 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 3,870,251 | USD | |
| At 2020-12-31 | 125,183 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | -7,058,937 | USD | |
| At 2020-12-31 | -2,516,283 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 3,870,251 | USD | |
| At 2020-12-31 | 67,120 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-12-31 | 4,570,345 | USD | 365 |
| 2020-08-13 to 2020-12-31 | 105,755 | USD | 141 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-12-31 | 27,691 | USD | 365 |
| 2020-08-13 to 2020-12-31 | 14,917 | USD | 141 |
Inspect the source
- Entity
- MOONLAKE IMMUNOTHERAPEUTICS / CIK 0001821586
- Captured
- 2026-09-21T17:28:56.515Z
- SEC response SHA-256
5ec7814562ed5c855b3116fa30aee75dd24e176ae565286831b8e7bddfac283a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001821586.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))